Isabel Santana1, Filipa Farinha2, Sandra Freitas3, Vítor Rodrigues4, Ålvaro Carvalho5. 1. Centro de Neurociências e Biologia Celular. Universidade de Coimbra. Coimbra. Portugal. Departamento de Neurologia. Faculdade de Medicina. Universidade de Coimbra. Coimbra. Portugal. Consulta de Demência. Serviço de Neurologia. Centro Hospitalar e Universitário de Coimbra. Coimbra. Portugal. 2. Serviço de Reumatologia. Centro Hospitalar do Baixo Vouga. Aveiro. Portugal. 3. Centro de Neurociências e Biologia Celular. Universidade de Coimbra. Coimbra. Portugal. Centro de Investigação. Núcleo de Estudos e Intervenção Cognitivo Comportamental (CINEICC). Universidade de Coimbra. Coimbra. Portugal. 4. Departamento de Epidemiologia e Medicina Preventiva. Faculdade de Medicina. Universidade de Coimbra. Coimbra. Portugal. 5. Departamento de Saúde Mental e Psiquiatria. Faculdade de Ciências Médicas. Universidade Nova de Lisboa. Lisboa. Portugal. Programa de Saúde Mental. Direcção Geral de Saúde. Lisboa. Portugal.
Abstract
INTRODUCTION: The incidence and prevalence of global dementia and Alzheimer's disease (AD) increase with age, almost doubling every five years after the sixth decade of life. Demographic aging is a reality in Portugal, being expectable that the number of dementia cases also increases. Even so, dementia-epidemiological data in Portugal is scarce and cost-of-illness studies are almost inexistent. Our aims were to obtain up-to-date information about the prevalence of dementia/ Alzheimer's disease in Portugal, to estimate the number of cases effectively diagnosed as Alzheimer's disease and to determine illness-costs with specific dementia treatment. MATERIAL AND METHODS: The numbers of age-adjusted prevalence of dementia obtained for Occidental Europe (Alzheimer's Disease International study), where applied to the resident population in Portugal (2013). Estimations related to diagnosis and treatment-costs were based in data provided by the Intercontinental Marketing Services Health (IMSH)-2013. RESULTS: The estimated number of Portuguese people with dementia among those aged ≥60 years, is 160,287, representing 5.91% of this population-stratum. Knowing Alzheimer's disease is responsible for 50-70% of all cases, we might conclude there are between 80,144 and 112,201 patients. According to IMSH-data, 76250 receive anti-dementia drugs and the costs of this kind of medication is 37 M€¬/year. CONCLUSIONS: As a consequence of the demographic aging, also the number of dementia cases increases. Apparently, not all Alzheimer's disease patients receive the recommended medication, suggesting this condition is still under-diagnosed. However, figures indicate a positive progression with an increment of treated cases and a reduction of medication-costs.
INTRODUCTION: The incidence and prevalence of global dementia and Alzheimer's disease (AD) increase with age, almost doubling every five years after the sixth decade of life. Demographic aging is a reality in Portugal, being expectable that the number of dementia cases also increases. Even so, dementia-epidemiological data in Portugal is scarce and cost-of-illness studies are almost inexistent. Our aims were to obtain up-to-date information about the prevalence of dementia/ Alzheimer's disease in Portugal, to estimate the number of cases effectively diagnosed as Alzheimer's disease and to determine illness-costs with specific dementia treatment. MATERIAL AND METHODS: The numbers of age-adjusted prevalence of dementia obtained for Occidental Europe (Alzheimer's Disease International study), where applied to the resident population in Portugal (2013). Estimations related to diagnosis and treatment-costs were based in data provided by the Intercontinental Marketing Services Health (IMSH)-2013. RESULTS: The estimated number of Portuguese people with dementia among those aged ≥60 years, is 160,287, representing 5.91% of this population-stratum. Knowing Alzheimer's disease is responsible for 50-70% of all cases, we might conclude there are between 80,144 and 112,201 patients. According to IMSH-data, 76250 receive anti-dementia drugs and the costs of this kind of medication is 37 M€¬/year. CONCLUSIONS: As a consequence of the demographic aging, also the number of dementia cases increases. Apparently, not all Alzheimer's diseasepatients receive the recommended medication, suggesting this condition is still under-diagnosed. However, figures indicate a positive progression with an increment of treated cases and a reduction of medication-costs.
Authors: Laetitia Teixeira; Pedro Machado Dos Santos; Sara Alves; Maria João Azevedo; Mafalda Gomes Duarte; António Leuschner; Constança Paúl Journal: Front Med (Lausanne) Date: 2017-11-13
Authors: Manuel Gonçalves-Pereira; Ana Cardoso; Ana Verdelho; Joaquim Alves da Silva; Manuel Caldas de Almeida; Alexandra Fernandes; Cátia Raminhos; Cleusa P Ferri; A Matthew Prina; Martin Prince; Miguel Xavier Journal: BMC Geriatr Date: 2017-11-07 Impact factor: 3.921
Authors: Victoria García-Morales; Anabel González-Acedo; Lucía Melguizo-Rodríguez; Teresa Pardo-Moreno; Víctor Javier Costela-Ruiz; María Montiel-Troya; Juan José Ramos-Rodríguez Journal: Biomedicines Date: 2021-12-14